This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba Fund for Health Services and Research, Chaim Sheba Medical Center to commence a Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (R/R AML). This investigator-led trial will be supervised by Professor Arnon Nagler, who was…
-
MST Access Investor Conference Presentation
Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021.
-
Race Executes Key Contract for Israel Phase 2 AML Trial
8 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed a contract with Trialog Clinical Trials Ltd, Israel, to support the coming combination Phase 2 Acute Myeloid Leukaemia trial. Trialog will supply the trial drugs (including Zantrene®) as well as provide other clinical services to Race and Chaim Sheba. This…
-
CEO Phil Lynch Talks to the Australian Shareholder Association Podcast
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene.
-
Race Executes Contract to Commence Phase 2 Extramedullary AML Trial
2 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has appointed the Contract Research Organisation (CRO), Parexel International, to support an open label Phase 1/2 clinical trial in patients with relapsed or refractory (r/r) extramedullary Acute Myeloid Leukemia (AML). The trial will be led by Principal Investigator Associate Professor Anoop Enjeti,…
-
Race appoints Professor Michael Kelso as Principal Scientist
20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Michael Kelso as Principal Scientist. Prof Kelso will be responsible for providing scientific leadership, developing, managing, and implementing Race’s preclinical and clinical research programs in collaboration with Race’s Chief Scientific Officer, Dr Daniel Tillett and Chief Medical Officer, Dr…
-
Race Oncology May 2021 Investor Update
Race Oncology updates our shareholders on our progress and clinical plans for 2021 and beyond.
-
MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Zantrene® Drug Combinations
Race Oncology Limited (“Race”) is pleased to announce a team of researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number of clinically translatable drug combinations that showed synergy with Zantrene® (bisantrene dihydrochloride) when tested in Acute Myeloid Leukaemia (AML) cells. This…
-
Race Placement closes oversubscribed & Bonus Option Issue launched for shareholders
Race Oncology Limited (ASX: RAC) is pleased to announce that it has received binding commitments to raise $5.4m (before associated costs) in an oversubscribed equity placement to new and existing institutional and sophisticated investors (Placement), and the commencement of a bonus issue of options to existing eligible shareholders of Race (Bonus Option Issue). “This new…